News | April 14, 2026
Roche wins CE mark for blood-based MS brain damage test
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
The approval now covers procedures using 10-14F inner diameter and up to 17F outer diameter procedural sheaths
The device aims to bring precision neuroscience into clinical trials, accelerating drug development
The enhanced allocation will be directed toward expanding healthcare infrastructure, increasing patient capacity, and widening acces
Drugmaker taps 1 million retail touchpoints, quick commerce and modern trade to expand ingredient-led skincare franchise
Landmark procedure restores 32-year-old CKD patient’s health, highlighting how public insurance is widening access to advanced renal care
20 among them to receive $20,000 grants
Backed by a £680,000 grant from Leeds Hospitals Charity, the study is jointly led by academics and clinicians from the University of Leeds and Leeds Teaching Hospitals NHS Trust
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
Subscribe To Our Newsletter & Stay Updated
